本文已被：浏览 888次 下载 346次
Received:December 13, 2018 Published Online:September 24, 2019
Received:December 13, 2018 Published Online:September 24, 2019
中文摘要: 目的观察辨证辨病结合的Ⅲb~Ⅳ 期非小细胞肺癌中医治疗方案的临床疗效。方法采用多中心、前瞻性、随机、对照的研究方法,将2015年10月至2017年1月收治的89例气阴两虚型Ⅲb～Ⅳ期非小细胞肺癌患者分为治疗组(予中医综合治疗方案)44例、对照组(予单独化疗治疗)45例。对照组予含铂两药化疗。治疗组在对照组的基础上,口服金复康口服液合软化汤,治疗2个周期后对患者进行定期随访。主要指标为近期疗效、生存质量、中医症状改善情况、免疫功能等。结果在瘤灶控制率方面,治疗组的靶病灶客观缓解率29.55%、疾病控制率 95.46%,对照组客观缓解率2.00%、疾病控制率73.1%,治疗组显著优于对照组(P<0.05);在体力状况评分方面,治疗组患者的KPS评分提高18例,稳定25例,下降1例,对照组提高1例,稳定29例,下降15例,治疗组较对照组有明显的改善(P<0.05);在临床证候积分的改善方面,治疗组积分变化显效5例,有效27例,无效12例,对照组积分变化显效1例,有效5例,无效39例,治疗组的中医证候疗效优于对照组(P<0.05)。结论金复康口服液合软化汤联合化疗可以稳定及缩小病灶,提高患者生活质量,改善气阴两虚型晚期肺癌化疗患者临床症状,具有较好的安全性。金复康口服液合软化汤联合化疗治疗气阴两虚型Ⅲb~Ⅳ 期非小细胞肺癌是一种行之有效的治疗方法。
Abstract:Objective To observe the clinical effect of Chinese medicine treatment of stage Ⅲb to Ⅳ non-small cell lung cancer (NSCLC) based on syndrome differentiation and disease differentiation. Methods A multicenter,prospective,randomized,controlled study was conducted.From October 2015 to January 2017,89 patients with stageⅢb to Ⅳ NSCLC with Qi and Yin deficiency were divided into treatment group (44 cases,treated with comprehensive treatment of Chinese medicine) and control group (45 cases,treated with chemotherapy alone).The control group received platinum-containing two-drug chemotherapy,and the treatment group received Jinfukang combined with Ruanhua decoction on the basis of control group treatment.All the patients were followed up regularly after 2 cycles of treatment.The main indicators were short-term efficacy,quality of life,improvement of Chinese medicine symptoms and immune function. Results In terms of tumor control rate,the objective remission rate of target lesions and disease control rate in treatment group were significantly higher than those in control group (29.55% vs 2.00%,95.46% vs 73.1%,all P<0.05).In the treatment group,the KPS score increased in 18 cases,stabilized in 25 cases and decreased in 1 case,while the KPS score improved in 1 case,stabilized in 29 cases and decreased in 15 cases in the control group.The physical condition score of the treatment group was significantly improved than that of the control group (P<0.05).In the improvement of clinical syndrome integral,the treatment group showed marked effect in 5 cases,effective in 27 cases,ineffective in 12 cases,and the control group showed marked effect in 1 case,effective in 5 cases and ineffective in 39 cases.The treatment group had better curative effect than the control group on Chinese medicine syndrome (P<0.05). Conclusion Jinfukang and Ruanhua decoction combined with chemotherapy can stabilize and narrow the focus,improve the quality of life,improve the clinical symptoms of patients with advanced lung cancer with deficiency of both Qi and Yin,and have good safety.It's an effective treatment for stage Ⅲb to Ⅳ NSCLC with Qi and Yin deficiency.
文章编号： 中图分类号：R 734.2，R 241.3 文献标志码：B
基金项目:国家卫生计生委医药卫生科技发展研究中心项目(SHDC12016114);十三五“重大新药创制”科技重大专项2017ZX09304001)
引用文本：